Publicacións en colaboración con investigadores/as de Harvard Medical School (8)

2023

  1. Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort

    Journal of Clinical Medicine, Vol. 12, Núm. 1

2022

  1. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

    The Lancet Oncology, Vol. 23, Núm. 3, pp. 362-373

2020

  1. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 12, pp. 1574-1588

2019

  1. Feedforward regulation of Myc coordinates lineage-specific with housekeeping gene expression during B cell progenitor cell differentiation

    PLoS Biology, Vol. 17, Núm. 4

2018

  1. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)

    Clinical Microbiology and Infection, Vol. 24, pp. S41-S52

  2. Management of unresectable, locally advanced pancreatic adenocarcinoma

    Clinical and Translational Oncology, Vol. 20, Núm. 2, pp. 113-118

2015

  1. New advances in genitourinary cancer: evidence gathered in 2014

    Cancer and Metastasis Reviews, Vol. 34, Núm. 3, pp. 443-464

2009

  1. Progenitor cells from the explanted heart generate immunocompatible myocardium within the transplanted donor heart

    Circulation Research, Vol. 105, Núm. 11, pp. 1128-1140